Recursion(US:RXRX)2025-08-05 10:33Clinical Programs and Collaborations - Recursion Pharmaceuticals has over 5 high potential clinical and pre-clinical programs across oncology and rare disease indications, with partnerships including Roche-Genentech, Sanofi, Bayer, and Merck KGaA[127]. - The ongoing Phase 1/2 DAHLIA trial for REC-1245 is focused on advanced solid tumors, with early preclinical data showing reduced viability in tumors characterized by replication stress[131]. - REC-617, a CDK7 inhibitor, has shown promising safety and efficacy signals in early Phase 1/2 results, including a durable partial response in a late-stage metastatic ovarian cancer patient[134]. - The collaboration with Sanofi has achieved $130 million in upfront and milestone payments, with potential for over $300 million in milestone payments for each program[134]. - The company is advancing multiple neuroscience target validation programs leveraging the Recursion OS and Genentech's biological expertise[140]. - Potential for over $100 million in partnership milestones by the end of 2026, with several programs advancing towards development candidate designation[134]. Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $171.9 million, compared to a net loss of $97.5 million for the same period in 2024, representing a 76% increase in losses[146]. - Total revenue for the three months ended June 30, 2025, was $19.2 million, a 33% increase from $14.4 million in the same period in 2024[146]. - Operating revenue increased by 33% to $19.1 million for the three months ended June 30, 2025, driven by collaborations with Sanofi, Roche, and Merck KGaA[148]. - Research and development expenses for the three months ended June 30, 2025, were $128.6 million, a 74% increase from $73.9 million in the same period in 2024[151]. - The cost of revenue for the three months ended June 30, 2025, was $20.2 million, more than doubling from $9.2 million in the same period in 2024[149]. - General and administrative expenses for the three months ended June 30, 2025, were $46.7 million, a 47% increase from $31.8 million in the same period in 2024[157]. - Other income for the three months ended June 30, 2025, was $4.3 million, a 74.6% increase from $2.5 million in the same period in 2024, primarily due to increased interest income[160]. Cash and Financing Activities - As of June 30, 2025, Recursion had cash and cash equivalents of $525.1 million, sufficient to fund operations for at least the next twelve months[142]. - The company anticipates needing to raise additional financing in the future to fund operations and potential product commercialization[144]. - Cash used in operating activities for the six months ended June 30, 2025, was $(208,375) thousand, an increase from $(184,519) thousand in 2024[165]. - Cash provided by financing activities in the six months ended June 30, 2025, was $138,186 thousand, down from $277,019 thousand in 2024[171]. - Cash provided by financing activities in 2025 included proceeds of $141.0 million from common stock issuances[171]. - Cash used in investing activities for the six months ended June 30, 2025, was $(13,078) thousand, compared to $(10,835) thousand in 2024[168]. - Cash used in investing activities in 2025 included $4.4 million from the disposal of Exscientia GmbH and $5.0 million for property and equipment purchases[168]. - In 2024, cash used in investing activities primarily consisted of $7.8 million for property and equipment purchases, including $2.9 million for upgrading the BioHive-2 supercomputer[169]. Restructuring and Operational Costs - Total restructuring costs for the first half of 2025 were $8.8 million, significantly higher than $1.1 million in the same period of 2024[137]. - The increase in cash used by operating activities in 2025 was attributed to higher costs from research and development and administrative expenses due to the acquisition of Exscientia, including $9.7 million in disposal-related payments and $10.4 million in severance payments[166]. Accounting and Financial Position - The accumulated deficit as of June 30, 2025, was $1.8 billion, reflecting significant operating losses since inception[163]. - As of June 30, 2025, cash and cash equivalents were primarily in money market funds, with interest income sensitivity affected by interest rate changes[175]. - There were no significant changes in the company's application of critical accounting policies during the six months ended June 30, 2025[173]. - The company has no formal hedging program for foreign currency, and a 10% change in exchange rates would have an insignificant effect on financial results[176].